3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Burkitt Lymphoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Down Syndrome
1
Interventions
Rituximab
17
Cyclophosphamide
15
Prednisone
12
Doxorubicin
10
Lenalidomide
9
ibrutinib
7
Vincristine
7
polatuzumab vedotin
5
obinutuzumab
5
Oxaliplatin
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
venetoclax
4
glofitamab
4
fludarabine
4
Specimen Handling
4
Biopsy
4
prednylidene
3
fludarabine phosphate
3
deltacortene
3
Whole-Body Irradiation
3
R-CHOP protocol
3
Etoposide
3
Cyclosporine
3
Bendamustine Hydrochloride
3
zanubrutinib
2
pembrolizumab
2
acalabrutinib
2
Prednisolone
2
Mycophenolic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
Methylprednisolone
×
30 days
×
Clear all
NCT06717347
2026-05-29
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,046 enrolled